TransCon IL-2 β/γ, a novel long-acting prodrug with sustained …
2022年6月2日 · TransCon IL-2 β/γ is a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 analog designed to optimally address these shortcomings. Methods: …
TransCon IL-2 β/γ alone or in combination with pembrolizumab, …
Background: TransCon IL-2 β/γ (TC-IL2 β/γ) is a novel prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 analog (IL-2 β/γ). IL-2 β/γ is transiently attached to an inert carrier by a …
IL-2 promotes the survival, proliferation and anti-tumor functions of CD8 cytotoxic T cells, CD4 e ector T cells and natural killer (NK) cells, which mostly express the dimeric IL-2Rβ/γ receptor …
Phase 1/2 dose escalation and dose expansion study of TransCon …
2023年5月31日 · Background: TransCon IL-2 β/γ is a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 analog (IL-2 β/γ) designed to optimally address the …
TransCon IL-2 β/γ: a novel long-acting prodrug with sustained …
2022年7月11日 · TransCon IL-2 β/γ is a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2. It has remarkable and durable pharmacodynamic effects in monkeys and …
TransCon IL-2 β/γ: a novel long-acting prodrug with ... - PubMed
TransCon IL-2 β/γ is a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2. It has remarkable and durable pharmacodynamic effects in monkeys and potential for …
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior …
The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of …
1034P Phase I/II dose escalation and dose ... - Annals of Oncology
TransCon IL-2 β/γ is a novel prodrug with sustained release of an IL-2 analog (IL-2 β/γ). It is created by permanently attaching a 5 kDa mPEG in the IL-2Rα binding site and transiently …
Engineering IL-2 to Give New Life to T Cell Immunotherapy
2021年1月27日 · We discuss recent studies that elucidate the potential of newly engineered IL-2-based therapeutics for cancer and autoimmune diseases. Keywords: IL-2; autoimmunity; …
Bempegaldesleukin (BEM-PEG), a novel CD122-preferential IL2 pathway agonist, prefer-entially binds the heterodimeric IL2bgR predominantly expressed on NK and CD8 T cells and …